Latest From Akriti Seth
Indoco has tripled its operating profit in its financial first quarter ended 30 June 2020. The company has also received FDA approval for its generic version of Eli Lilly’s Zyprexa.
Based on its “solid track record of filing, getting approval and launching high-value generics,” Amneal not only plans to launch eight new “high value” products over the next year, the company also plans to file for another 20-25 generics. Amneal has 91 products in the pipeline awaiting FDA approval and 132 products actively in development, mainly in non-oral solid dosage forms.
To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.
Dr Reddy’s saw growth particularly in Europe, North America and international markets in the firm’s financial first quarter ended June 2020. However, the company’s domestic business saw a decline of a due to the impact of COVID-19.
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.